8-hydroxy-2-(di-n-propylamino)tetralin has been researched along with Anochlesia in 32 studies
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.
8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively
| Excerpt | Relevance | Reference |
|---|---|---|
| "or s." | 5.72 | The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. ( Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A, 2022) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 5.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "or s." | 1.72 | The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. ( Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A, 2022) |
| "Treatment with fluoxetine did not affect the motor coordination caused by haloperidol." | 1.51 | The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms. ( Ahmadi, SA; Haddadi, R; Sabahi, M, 2019) |
| "Aripiprazole is a first next-generation atypical antipsychotic drug with dopamine system stabilizing, serotonin (5-hydroxytryptamine, 5-HT) 5-HT1A receptor partial agonistic, and 5-HT2A receptor antagonistic properties." | 1.35 | Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. ( Abe, M; Egashira, N; Fujiwara, M; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R, 2008) |
| "THC (10 mg/kg, i." | 1.33 | Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. ( Egashira, N; Fujiwara, M; Iwasaki, K; Koushi, E; Matsuda, T; Mishima, K; Shoyama, Y, 2006) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Lesopitron inhibits haloperidol-induced catalepsy that is the consequence of its action on 5-HT1A autoreceptors." | 1.32 | Effects of lesopitron on the central nervous system arising from its interaction with 5-HT1A receptors. ( Camarasa, J; Escubedo, E; Farré, A; Fisas, MA, 2004) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 1.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "HAL-induced catalepsy, while reduced by the systemic administration of the 5-HT(1A) agonist 8-OH-DPAT (0." | 1.31 | Central 5-HT(4) receptors and dopamine-dependent motor behaviors: searching for a functional role. ( Cervo, L; De Deurwaerdère, P; Spampinato, U; Stinus, L, 2002) |
| "In this study, both catalepsy and changes in extracellular levels of striatal dopamine (DA) and dihydroxyphenyl acetic acid (DOPAC) induced by the typical neuroleptic haloperidol (HAL) were simultaneously assessed, using intracerebral microdialysis in freely moving rats, in the presence of either the 5-HT1A agonist 8-OH-DPAT or the 5-HT2A/C antagonist ritanserin." | 1.30 | 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. ( Bonhomme, N; De Deurwaerdère, P; Le Moal, M; Lucas, G; Spampinato, U, 1997) |
| "Raclopride induced catalepsy in rats, whereas like clozapine, S 14506 was virtually ineffective." | 1.29 | Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents. ( Arbaoui, J; Chagraoui, A; Mocaër, E; Protais, P, 1994) |
| "4." | 1.29 | Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. ( Andersen, HL; Kilpatrick, IC, 1996) |
| "The lack of catalepsy of clozapine, therefore, cannot be addressed primarily to clozapine's agonistic activity at 5-HT1A receptors." | 1.29 | 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. ( Bartoszyk, GD; Roos, C; Ziegler, H, 1996) |
| "120 min)." | 1.28 | Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. ( Wadenberg, ML, 1992) |
| "Morphine-induced catalepsy was enhanced by fenfluramine and attenuated by metergoline, whereas neither fenfluramine nor metergoline had any effect on haloperidol-induced catalepsy." | 1.27 | Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. ( Berendsen, HH; Broekkamp, CL; Oosterloo, SK; van Delft, AM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.25) | 18.7374 |
| 1990's | 16 (50.00) | 18.2507 |
| 2000's | 9 (28.13) | 29.6817 |
| 2010's | 4 (12.50) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Kołaczkowski, M | 2 |
| Marcinkowska, M | 1 |
| Bucki, A | 1 |
| Pawłowski, M | 1 |
| Mitka, K | 1 |
| Jaśkowska, J | 1 |
| Kowalski, P | 1 |
| Kazek, G | 1 |
| Siwek, A | 1 |
| Wasik, A | 1 |
| Wesołowska, A | 2 |
| Mierzejewski, P | 1 |
| Bienkowski, P | 1 |
| Jastrzębska-Więsek, M | 1 |
| Varney, MA | 1 |
| Newman-Tancredi, A | 3 |
| Depoortere, R | 2 |
| Ahmadi, SA | 1 |
| Sabahi, M | 1 |
| Haddadi, R | 1 |
| Kulikova, EA | 1 |
| Bazovkina, DV | 2 |
| Akulov, AE | 1 |
| Tsybko, AS | 1 |
| Fursenko, DV | 1 |
| Kulikov, AV | 4 |
| Naumenko, VS | 1 |
| Ponimaskin, E | 1 |
| Kondaurova, EM | 1 |
| Ohno, Y | 1 |
| Shimizu, S | 1 |
| Imaki, J | 1 |
| Ishihara, S | 1 |
| Sofue, N | 1 |
| Sasa, M | 1 |
| Kawai, Y | 1 |
| Egashira, N | 2 |
| Okuno, R | 1 |
| Matsushita, M | 1 |
| Abe, M | 1 |
| Mishima, K | 2 |
| Iwasaki, K | 2 |
| Nishimura, R | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 2 |
| Auclair, AL | 1 |
| Kleven, MS | 2 |
| Barret-Grévoz, C | 1 |
| Barreto, M | 1 |
| Terenina, EE | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Fisas, MA | 1 |
| Farré, A | 1 |
| Camarasa, J | 1 |
| Escubedo, E | 1 |
| Haleem, DJ | 1 |
| Shireen, E | 1 |
| Haleem, MA | 1 |
| Matsuda, T | 1 |
| Koushi, E | 1 |
| Shoyama, Y | 1 |
| Wadenberg, ML | 5 |
| Hillegaart, V | 2 |
| Corbett, R | 1 |
| Hartman, H | 1 |
| Kerman, LL | 1 |
| Woods, AT | 1 |
| Strupczewski, JT | 1 |
| Helsley, GC | 1 |
| Conway, PC | 1 |
| Dunn, RW | 1 |
| Protais, P | 1 |
| Chagraoui, A | 1 |
| Arbaoui, J | 1 |
| Mocaër, E | 1 |
| Popova, NK | 3 |
| Avgustinovich, DF | 2 |
| Vishnivetskaia, GB | 1 |
| Kolpakov, VG | 3 |
| Maslova, GB | 1 |
| Kozintsev, I | 1 |
| Cortizo, L | 1 |
| Ahlenius, S | 2 |
| Berge, OG | 1 |
| Andersen, HL | 1 |
| Kilpatrick, IC | 1 |
| Bartoszyk, GD | 1 |
| Roos, C | 1 |
| Ziegler, H | 1 |
| Fdez Espejo, E | 1 |
| Gil, E | 1 |
| Lucas, G | 1 |
| Bonhomme, N | 1 |
| De Deurwaerdère, P | 2 |
| Le Moal, M | 1 |
| Spampinato, U | 2 |
| Plyusnina, IZ | 1 |
| Audinot, V | 1 |
| Gobert, A | 1 |
| Rivet, JM | 1 |
| Brocco, M | 1 |
| Lejeune, F | 1 |
| Gluck, L | 1 |
| Desposte, I | 1 |
| Bervoets, K | 1 |
| Dekeyne, A | 1 |
| Millan, MJ | 1 |
| Ninan, I | 1 |
| Kulkarni, SK | 1 |
| Prinssen, EP | 1 |
| Koek, W | 1 |
| Colpaert, FC | 1 |
| Cervo, L | 2 |
| Stinus, L | 1 |
| Invernizzi, RW | 1 |
| Samanin, R | 1 |
| Broekkamp, CL | 1 |
| Oosterloo, SK | 1 |
| Berendsen, HH | 1 |
| van Delft, AM | 1 |
32 other studies available for 8-hydroxy-2-(di-n-propylamino)tetralin and Anochlesia
| Article | Year |
|---|---|
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; C | 2014 |
The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Buspirone; Catalepsy; Depres | 2022 |
The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Catalepsy; Fluoxetine; Haloperidol; Male | 2019 |
Alterations in pharmacological and behavioural responses in recombinant mouse line with an increased predisposition to catalepsy: role of the 5-HT1A receptor.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Male; Mice; Mice, Inbred C57BL; Mice, In | 2016 |
Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Disea | 2008 |
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavi | 2008 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Ben | 2009 |
Effect of selective agonist of serotonin 5-HT1A receptors on defensive behavior in mice with different predisposition to catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Analysis of Variance; Animals; Catalepsy; Dose-R | 2010 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Effects of lesopitron on the central nervous system arising from its interaction with 5-HT1A receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Central Nervous System; Central Nervous | 2004 |
Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain Chemistry; Buspirone; Catal | 2004 |
Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Catalepsy; Dose-Response Relationship, D | 2006 |
Stimulation of median, but not dorsal, raphe 5-HT1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoreceptors; Catalepsy; Dopamine Antagonists; Inj | 1995 |
Effects of atypical antipsychotic agents on social behavior in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Ca | 1993 |
Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Benzamides; Benzazepines; Catalep | 1994 |
[Participation of brain 5-HT1A serotonin receptors in regulating hereditary catalepsy].
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Binding Sites; Catalepsy; Cerebral Cortex; Corpus S | 1994 |
Effect of selective 5-HT1A agonists and 5-HT2 antagonists on inherited catalepsy in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Catalepsy; Dose-Response Relation | 1994 |
Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Betaxolol; Catalepsy; Dopamine D2 Receptor Antagoni | 1994 |
Supraspinal mediation of dopamine-serotonin interactions in extrapyramidal motor functions in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Corpus Striatum; Dopamine; Dopamine D2 R | 1993 |
Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; C | 1996 |
5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Catalepsy; Clozapine; Haloper | 1996 |
Single restraint stress sensitizes acute chewing movements induced by haloperidol, but not if the 5-HT1A agonist 8-OH-DPAT is given prior to stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Catalepsy; | 1997 |
8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Dopamine; Haloperidol; Male; Rats; Rats, | 1997 |
Specific [3H]8-OH-DPAT binding in brain regions of rats genetically predisposed to various defense behavior strategies.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Animals; Brain Chemistry; Catalepsy; Genetics, B | 1998 |
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
Topics: 2-Naphthylamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzopyrans; Binding, Competitive; | 1998 |
Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Benzodiazepines; Catalepsy; C | 1999 |
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behav | 2000 |
Central 5-HT(4) receptors and dopamine-dependent motor behaviors: searching for a functional role.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Apomorphine; Catalepsy; Central Nervous System; Dop | 2002 |
Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Avoidance Learning; Benzazepines; Catalepsy; Dopami | 1992 |
Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy | 1991 |
8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis.
Topics: 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Haloperidol; Ma | 1988 |
Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Drug Interactions; Fenfluramine; Haloper | 1988 |